Amgen and Array BioPharma have entered a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early lead development. “We are pleased to enter this collaboration with Array that builds on our continued focus in inflammation, one of Amgen’s key strategic areas of interest,” s...